VEGFR1(Vascular endothelial growth factor receptor 1), also known as FLT-1(Fms-like tyrosine kinase 1), is belongs to the class III subfamily of receptor tyrosine kinases. While family members VEGFR1, VEGFR2and VEGFR3 are all mainly expressed on endothelial cells, only VEGFR1 is expressed on macrophages, and mainly plays inhibitory roles. Inhibitors of VEGFR are used in the treatment of cancer. It acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 binds VEGF with higher affinity than does VEGFR2, but shows weaker kinase activity. The VEGF kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. Recombinant human VEGFR1/Flt-1, fused to hIgG-Tag at C-terminal, was expressed in HEK293 cell and purified by using conventional chromatography techniques. Source: Recombinant protein corresponding to aa27-328 from human VEGFR1, fused to hlgG-Tag at C-terminal, expressed in HEK293. Molecular Weight: ~60.3kD (535aa) Amino Acid Sequence: SKLKDPELSL KGTQHIMQAG QTLHLQCRGE AAHKWSLPEM VSKESERLSI TKSACGRNGK QFCSTLTLNT AQANHTGFYS CKYLAVPTSK KKETESAIYI FISDTGRPFV EMYSEIPEII HMTEGRELVI PCRVTSPNIT VTLKKFPLDT LIPDGKRIIW DSRKGFIISN ATYKEIGLLT CEATVNGHLY KTNYLTHRQT NTIIDVQIST PRPVKLLRGH TLVLNCTATT PLNTRVQMTW SYPDEKNKRA SVRRRIDQSN SHANIFYSVL TIDKMQNKDK GLYTCRVRSG PSFKSVNTSV HI Biological Activity: Measured by its ability to inhibit proliferation using HUVEC human umbilical vein endothelial cells in the presence of Human VEGF165. The ED50 range 60ng/ml. Applications: Suitable for use in SDS-PAGE, Bioactivity. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 6 months after receipt at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.